TNFSF13B and systemic lupus erythematosus: The baseline whole blood microarray analysis from SLE patients enrolled in the tabalumab (anti-BAFF) phase III trials also linked increased LYN expression to disease activity, IFN-I signature expression, and anti-dsDNA antibodies through weighted gene co-expression network analysis, identifying LYN in the ‘inflammatory response’ module (245).